Crystalline forms of 1-(2-(1H-imidazol-4-yl) ethyl) piperidine-2, 6-dione and uses thereof

By developing new 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione crystal form, the problems of insufficient dosage form stability and bioavailability were solved, and the drug was realized Efficient storage and rapid treatment effects have expanded the scope of cough treatment.

CN118922413APending Publication Date: 2024-11-08OBSHCHESTVO S OGRANICHENNOJ OTVETABTVENNOSTJU VALENTA INTELLEKT +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380028213.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-29
Filing Date
2023-03-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing dosage forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione have insufficient stability, therapeutic efficacy and bioavailability, resulting in their activity during the shelf life. The physical and chemical properties of the substances change significantly, affecting the development speed of therapeutic effects.

Method used

A new crystal form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione has been developed, with reduced hygroscopicity and improved storage stability while maintaining Good solubility and bioavailability, improve the compressibility and fluidity of the drug, avoid static electricity, and characterize its crystal form through the X-ray powder diffraction pattern obtained by Cu(Kα) radiation.

Benefits of technology

Improves the storage stability and bioavailability of drugs, ensures rapid development of therapeutic effects, expands the range of drugs used to treat and prevent coughs, and maintains the chemical and physical properties of drugs for a long time.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005046559360000011
    Figure BDA0005046559360000011
  • Figure BDA0005046559360000041
    Figure BDA0005046559360000041
  • Figure BDA0005046559360000042
    Figure BDA0005046559360000042
Patent Text Reader

Abstract

The present invention relates to the field of medicine, pharmacology and chemistry and pharmaceutical industry, and more particularly to novel crystalline forms of 1-(2-(1H-imidazol-4-yl)-ethyl) piperidine-2, 6-dione and pharmaceutical compositions and medicaments comprising the same, which can be used for the treatment and prevention of cough.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to the fields of medicine, pharmacology, chemistry and pharmaceutical industry, and more particularly to a new crystalline form of 1-(2-(1H-imidazol-4-yl)-ethyl)piperidine-2,6-dione, including a pharmaceutical composition and a pharmaceutical dosage form thereof, which can be used for treating and / or preventing cough. Prior art

[0002] Cough is one of the main complaints of patients for whom they often seek medical help. Usually, the reason is the nature of the cough, which is related to the patient's quality of life. It is generally believed that cough is a symptom of diseases related to damage to the human respiratory system. However, during severe coughing, intrathoracic pressure and airflow velocity increase, which may lead to various complications. These include, in particular, neurological diseases, such as depression, headache, fear of dangerous diseases, etc. (see PV Dicpinigaitis et al., Prevalence of depressive symptoms among patients with chronic cough, Chest, 2006, vol. 130, no. 6, pp. 1839-1843, doi: 10.1378 / chest. 130.6.1839).

[0003] Therefore, the technical problem of finding an effective method for preventing and treating cough is urgent to be solved.

[0004] RU 2562773 C2 discloses 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and its use for the treatment of viral diseases.

[0005]

[0006] In addition, RU2552929C1 discloses its use for treating eosinophilic diseases, and WO2019050429A1 discloses its use for treating diseases associated with abnormal cytokine activity. RU2020106386 discloses a liquid oral dosage form comprising 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione. WO2020106191A1 discloses the use of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione for treating diseases in patients with steroid resistance, in particular for the symptomatic treatment of asthma, rheumatoid arthritis, systemic lupus erythematosus, gastric disease and cough. The prior art does not provide information on the characteristics and pharmaceutical uses of the crystalline form of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione.

[0007] In addition, it should be noted that another urgent and local issue is the development of dosage forms with a therapeutic effect that develops at an accelerated rate in order to prevent the occurrence of serious consequences. This is more relevant for symptomatic drugs.

[0008] It should be further noted that one of the drawbacks of most pharmaceuticals is the lack of stability of the active substance during the shelf life. Medicaments and pharmaceutical compositions should be storable for long periods of time without the physicochemical properties of the active ingredient showing significant changes.

[0009] Unsolved technical problems are the inadequacy of the stability, therapeutic effectiveness and pharmacokinetic parameters (speed of development of therapeutic effect and bioavailability) of the dosage form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione. Summary of the invention

[0010] Technical Effects

[0011] The object of the present invention is to develop a new form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione which is storage-stable, non-hygroscopic and has an optimal set of physicochemical and pharmacokinetic parameters.

[0012] The inventors have surprisingly discovered that new crystalline forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, which were previously unknown in the prior art, have reduced hygroscopicity and increased storage stability while maintaining good solubility. In addition, active drug substances comprising specific new crystalline forms have improved compressibility as well as good flow properties without significant electrostatic phenomena while maintaining their therapeutic effectiveness. The new crystalline forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione also have increased bioavailability, which is particularly manifested in the rapid development of the therapeutic effect. These properties also apply to pharmaceutical compositions and medicaments comprising the new crystalline forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione.

[0013] The technical effects to be achieved by the present invention are as follows:

[0014] - Improved storage stability (3 years) of forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and active drug substances, pharmaceutical compositions and dosage forms comprising the same;

[0015] - Improve the long-term (10 years) stability of forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and active drug substances, pharmaceutical compositions and dosage forms comprising the same;

[0016] - reducing hygroscopicity while maintaining sufficient solubility of the form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione;

[0017] - Improve the compressibility of active drug substances, pharmaceutical compositions and dosage forms comprising forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione while maintaining good flowability without significant electrostatic phenomena;

[0018] - Improve the therapeutic effectiveness of forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and active drug substances, pharmaceutical compositions and dosage forms comprising the same;

[0019] -1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and active drug substances, pharmaceutical compositions and dosage forms comprising the same, and improved bioavailability, accelerated rate of development of therapeutic effects; and

[0020] - Expand the range of medicines used to treat and prevent cough.

[0021] Stability is understood as the ability of a substance, active drug substance, pharmaceutical composition and pharmaceutical form to retain chemical, physical, microbiological and biopharmaceutical properties within certain limits over a chosen period of time.

[0022] Hygroscopicity is understood as the ability of a substance to absorb water vapor (moisture) from the air. The degree and intensity of water vapor absorption depends on the chemical composition of the substance, the form of the substance and the amount of water vapor in the air.

[0023] Compressibility is understood as the ability of powder particles to agglomerate under pressure to form a stable solid dosage form. The flowability of a dosage form characterizes the ability of a powder to uniformly fill a given form.

[0024] Therapeutic effectiveness is understood as the ability of a drug to provide a pharmacological effect. The therapeutic effectiveness of any particular drug can be determined by evaluating the response of a patient or animal after administration of the drug; in this case, a drug with a high therapeutic effectiveness will provide greater symptom relief and / or symptom disappearance than a drug with a low therapeutic effectiveness.

[0025] Different crystalline and amorphous forms of a particular active substance may have different properties, such as dissolution profiles, melting points, stability, hygroscopicity, particle shape, density, bioavailability, chargeability, compressibility, flowability, etc. These properties should be considered in drug manufacturing. In particular, strong chargeability and low compressibility do not allow for the acquisition of dosage forms such as tablets. Drug compounds should have high solubility and long storage time without exhibiting significant changes in physicochemical properties, such as not being saturated with water, which may lead to changes in the drug's chemical composition and to loosening and disintegration of dosage forms such as tablets.

[0026] Crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0027] Due to the new crystal form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, the technical problem is solved and the specified technical effect is achieved.

[0028]

[0029] 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione can be represented as a meso structure. The present invention includes crystalline forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione regardless of the method of describing the meso structure. The meso structure includes:

[0030] The meso form of the imidazole group:

[0031]

[0032] For example, 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and 1-(2-(1H-imidazol-5-yl)ethyl)piperidine-2,6-dione are meso-forms. Therefore, "crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione" and "crystalline form of 1-(2-(1H-imidazol-5-yl)ethyl)piperidine-2,6-dione" are equivalent concepts. The names "1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione" and "1-[2-(1H-imidazol-4-yl)ethyl]piperidine-2,6-dione" are also equivalent.

[0033] A meso structure is understood as a structure in chemical resonance theory that arises due to the conjugation of multiple bonds and / or lone electron pairs in a molecule. In 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, a meso effect may exist at the imidazole group.

[0034] The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to the present invention can be characterized by the peak positions, 2θ (degrees) in the X-ray powder diffraction pattern obtained using Cu (Kα) radiation: 16.3±0.2, 23.8±0.2 and 24.5±0.2. In a preferred embodiment, the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to the present invention can be characterized by the peak positions, 2θ (degrees) in the X-ray powder diffraction pattern obtained using Cu (Kα) radiation: 16.3±0.2, 23.4±0.2, 23.7±0.2, 23.8±0.2, 24.5±0.2, 26.6±0.2 and 27.0±0.2. In another embodiment, the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to the present invention can be characterized by the peak positions, 2θ (degrees) in the X-ray powder diffraction pattern obtained using Cu(Kα) radiation: 11.9±0.2, 15.2±0.2, 16.3±0.2, 23.0±0.2, 23.4±0.2, 23.7±0.2, 23.8±0.2, 24.5±0.2, 26.6±0.2, 27.0±0.2, 28.3±0.2, 35.9±0.2 and 47.1±0.2. In a more preferred embodiment, the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to the present invention can be characterized by the peak positions, 2θ (degrees) in the X-ray powder diffraction pattern obtained using Cu(Kα) radiation. Figure 1 The X-ray powder diffraction pattern is shown.

[0035] In another embodiment, the crystal form of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione according to the present invention can be characterized by the lattice system and the crystal unit cell parameters. The unit cell is a parallelepiped built on the lattice nodes, and its parallel transfer (translation) in three dimensions can construct the entire lattice. The parameters of the lattice are the values ​​of the axes (a, b and c) and the values ​​of the angles (α, β and γ) therebetween. In a preferred embodiment, the lattice system of the crystal form of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione according to the present invention is an orthorhombic system. In the crystal of the orthorhombic system, the crystal is composed of a rectangular parallelepiped (α=β=γ=90°). The lattice parameter of the orthorhombic system is the size of the axis. In the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to the present invention, the axial value at room temperature (296.15K) is (in angstroms, ) 9.5±0.3, 15.0±0.3 and 15.0±0.3, and preferably 9.4835, 15.0520 and 14.9745. It should be taken into account that the observed unit cell parameters depend on the measurement temperature.

[0036] In the context of the present invention, the term "crystal form" is understood as a substance in solid form in which the molecules occupy ordered positions in space and form a crystal lattice. The ordered positions of molecules in the crystal lattice are called long-range order. The structure of a certain chemical composition as a result of any physical and chemical influence (mechanical, thermal, pressure, humidity, dissolution in various solvents under different conditions) can greatly change its properties. In most cases, this is caused by changes in the crystal structure or deformation of this structure under the influence of external forces or internal stresses. Some pharmaceutical active substances can form more than one type of crystal structure. Crystal forms that differ in crystal structure and properties are called polymorphs. Drug substances can also exist in an amorphous phase. The difference between the amorphous state of a substance and the crystalline state is that the mutual arrangement of atoms or molecules in the substance lacks order (long-range order of the relative arrangement of molecules), intermolecular distances and higher internal energy.

[0037] Powder X-ray diffraction is often used to study crystal forms.

[0038] Powder X-ray diffraction allows the identification of even minute changes in the state of the atomic lattice of a crystal, changes that cannot be detected by other methods. X-ray diffraction of polycrystalline samples allows the determination of the state of the solid (various crystalline and amorphous forms or a combination thereof). Structural studies are of the utmost importance. Determining the relationship between the atomic structure and the properties of a substance allows the establishment of a rational control of the process and reveals the reasons for the variations of these properties under the influence of one or another factor and allows the process for the preparation of a pharmaceutical substance to be managed more deliberately and changed in an appropriate direction.

[0039] Powder X-ray diffraction is based on the recording and subsequent analysis of the diffraction pattern produced by the diffraction of X-rays on a powder or polycrystalline sample of the material under study. In general, a crystal can be represented as a series of planes at an angle of θ to the direction of the X-ray beam. During diffraction, a detector or photographic film is used to record the X-rays. In order to obtain the diffraction pattern from a crystalline powder, the intensity of the scattered radiation is measured according to the angle 2θ between the sample and the primary beam. According to the Wulff-Bragg formula nλ=2dsinθ, the interplanar spacing in the crystal can be calculated. The data obtained for each substance are strictly independent, so the X-ray diffraction pattern clearly characterizes the substance under study (see GPM.1.2.1.1.0011.15 X-ray Powder Diffractometry). In the X-ray diffraction pattern, crystalline substances show separate, clear narrow lines (clear peaks), and amorphous substances show wide, fuzzy peaks (halos).

[0040] Pharmaceutical composition

[0041] The technical problem is solved and the specified technical effect is achieved due to the pharmaceutical composition for treating and / or preventing cough comprising the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention and at least one pharmaceutically acceptable excipient.

[0042] Pharmaceutical composition means a composition (mixture, formulation, etc.) suitable for human or animal use and comprising an active drug substance. The active drug substance in the pharmaceutical composition includes an active substance that is a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention. Those skilled in the art will understand that the pharmaceutical composition of the present invention will also include a composition comprising one or more other active drug ingredients.

[0043] In the context of the present invention, the terms "include" and "comprise" mean that the specified pharmaceutical composition (drug, group of components, etc.) includes the following components / ingredients, but does not exclude the addition of other components / ingredients.

[0044] Preferably, the pharmaceutical composition is in solid form. Examples of solid dosage forms are powders, granules, agglomerates, capsules, tablets, dragees, etc. It will be appreciated by those skilled in the art that the pharmaceutical composition of the present invention can be in any other form that ensures that the active characteristics of the active drug substance are maintained. Most preferably, the solid form is a powder, granules, capsules or tablets. Powder is a solid non-dosage form, consisting of solid single dry particles of different dispersities, with flowability. Capsules are solid dosage forms or non-dosage forms, including hard (usually gelatinous) coatings that encapsulate one or more active substances, with or without the addition of excipients. Granules are solid dosage forms in the form of round, cylindrical or irregularly shaped agglomerates (aggregates of powder particles), including one or more active ingredients and with the addition of excipients. Tablets are solid dosage forms, most commonly prepared by compressing powders or granules including one or more active ingredients, with or without the addition of excipients.

[0045] The quantitative content of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione in the pharmaceutical composition is selected from the range of 0.01 to 99.99wt.%, preferably 1.00 to 80.00wt.%, more preferably 10.00 to 60.00wt.%, for example 5.00wt.%, 10.00wt.%, 15.00wt.%, 20.00wt.%, 25.00wt.%, 30.00wt.%, 35.00wt.%, 40.00wt.%, 45.00wt.%, 50.00wt.%, 55.00wt.%, 60.00wt.%.

[0046] In another preferred embodiment, the pharmaceutical composition comprises an effective amount of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention.

[0047] In the context of the present invention, the term "effective amount" is understood to be an amount of a pharmaceutical composition or drug that is sufficient to produce such a therapeutic effect on a disease, disorder or symptom when administered to a subject. An "effective amount" may vary, for example, depending on the form in which the substance is present, the nature of the disease, disorder and / or symptoms of the disease or disorder, the severity of the disease, disorder and / or symptoms of the disease or disorder, the age of the subject to be treated, and / or the weight of the subject to be treated. In any particular case, the appropriate amount will be apparent to those skilled in the art or may be determined by routine experimentation.

[0048] In a preferred embodiment, the crystalline form of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione is contained in a pharmaceutical composition or a medicament and is used at a specific dose. The dosage of the crystalline form of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione according to the present invention may be in the range of 1 mg to 1000 mg per day, preferably 60 mg to 500 mg. Preferably, in the solid form of the pharmaceutical composition or medicament, 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione is present in an amount corresponding to the recommended dose.

[0049] As used herein, the term "dose" characterizes the content of one or more active substances according to the dosage form in quantitative terms per unit dose, or unit volume, or unit weight, or for some types of dosage forms, the amount of active substance released from the dosage form per unit time.

[0050] The pharmaceutical composition of the present invention comprises at least one pharmaceutically acceptable excipient, which is a carrier of the active substance, providing the required volume / weight and necessary characteristics of the drug in a specific dosage form. Preferably, the pharmaceutical composition comprises a pharmaceutically acceptable excipient selected from the group consisting of fillers, binders, lubricants, disintegrants, glidants, preservatives, flavoring agents and coloring agents.

[0051] The term "excipient" or "diluent" means an additive used to form a solid dosage form into a given volume or weight. Such excipients may include starch, glucose, sucrose, lactose (milk sugar), basic magnesium carbonate, magnesium oxide, sodium chloride, sodium bicarbonate, clay (kaolin), gelatin, microcrystalline cellulose (MCC), methylcellulose (MC), sodium carboxymethylcellulose (Na CMC), calcium carbonate, disubstituted calcium phosphate, glycine (aminoacetic acid), dextrin, amylopectin, super amylopectin, sorbitol, mannitol, pectin, etc. The group is not limited to this list.

[0052] The term "binder" means a substance included in the weight of the tablet to provide it with the necessary viscosity. Such binders may include water, ethanol, starch paste, syrup, solutions of carboxymethylcellulose (CMC), hydroxyethylcellulose (HEC), hydroxypropylmethylcellulose (HPMC), polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), alginic acid, sodium alginate, gelatin, etc. The group is not limited to this list.

[0053] The term "glidant" is understood as an auxiliary substance used during the compression stage of the tablet manufacturing process to improve the flow of granules or powders by reducing the friction between the particles. Such glidants may include one or more of starch, talc, polyethylene oxide-4000, stearic acid, calcium stearate and magnesium stearate, etc. The group is not limited to this list.

[0054] The term "lubricant" means an excipient that helps reduce the friction between the tablet surface and the wall of the punch cup in which the tablet is formed, which is used during the compression stage in the process of producing tablets. Lubricants can include one or more of magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol (molecular weight greater than 3350), sodium lauryl sulfate, talc, mineral oil, leucine and poloxamer, etc. The group is not limited to this list.

[0055] The term "disintegrant" means a substance used to provide mechanical destruction of tablets in a liquid medium to improve disintegration or dissolution, which is necessary for rapid release of the active substance. Disintegrants can be one or more of microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked vinblastine, sodium starch glycolate, starch, pectin, gelatin, amylopectin, super amylopectin, agar, alginic acid, potassium alginate and sodium alginate, Tween-80, etc. The group is not limited to this list.

[0056] Other ingredients (flavoring agents) are used to improve taste (sweeteners) and smell (flavoring agents). For example, these include sugar, cocoa, vanillin. Dyes (pigments) are used to improve the appearance of pharmaceutical compositions and dosage forms. Examples of dyes are titanium dioxide, indigo carmine.

[0057] Those skilled in the art can select the amount, formulation and form of pharmaceutically acceptable excipients as long as the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione is fully or partially retained.

[0058] In a preferred embodiment, the pharmaceutical composition according to the present invention comprises (wt. %):

[0059] 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione crystalline form 20.0-30.0%

[0060] excipient:

[0061]

[0062] In a more preferred embodiment, the pharmaceutical composition according to the present invention comprises (wt.%):

[0063] Crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione 22.2%

[0064] excipient:

[0065]

[0066]

[0067] In a more preferred embodiment, the pharmaceutical composition according to the present invention comprises:

[0068] 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione crystalline form 40.00 mg

[0069] excipient:

[0070]

[0071] The administration routes of the pharmaceutical composition of the present invention include, but are not limited to, oral, inhalation, topical, transdermal, sublingual and rectal routes. In a preferred embodiment, the pharmaceutical composition is administered orally or sublingually.

[0072] In some embodiments, the pharmaceutical compositions of the present invention can be prepared using conventional methods known in the pharmaceutical field.

[0073] drug

[0074] The technical problem is solved and the specified technical effect is achieved due to the pharmaceutical product for treating and / or preventing cough comprising the crystalline form or pharmaceutical composition of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention.

[0075] Drugs (medicaments) refer to active pharmaceutical substances or pharmaceutical compositions in dosage forms suitable for human or animal use.

[0076] In a preferred embodiment, the present invention relates to drugs in solid dosage form. The dosage forms of the present invention include, but are not limited to, tablets, particularly oral tablets, effervescent tablets, film-coated tablets, sustained-release tablets, conventional tablets, controlled-release tablets, orally dispersible tablets, freeze-dried instant tablets, etc.; capsules, such as hard capsules, soft capsules, gelatin capsules, etc.; injection powders, such as freeze-dried injection powders, conventional injection powders, etc.; solutions, aerosols, sprays, transdermal drugs such as patches, granules, suppositories, and other dosage forms.

[0077] Those skilled in the art will appreciate that the medicament of the present invention may be in any form which ensures that the positive properties of the active drug substance are maintained.Most preferably, the solid form is a powder, granules, capsule or tablet.

[0078] The medicaments of the present invention may be active drug substances and pharmaceutical compositions comprising a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione. Preferably, the medicament further comprises at least one pharmaceutically acceptable excipient, however, its presence is optional.

[0079] The quantitative content of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione in the drug is selected from the range of 0.01 to 100wt.%, preferably 1.00 to 80.00wt.%, more preferably 10.00 to 60.00wt.%, for example 5.00wt.%, 10.00wt.%, 15.00wt.%, 20.00wt.%, 25.00wt.%, 30.00wt.%, 35.00wt.%, 40.00wt.%, 45.00wt.%, 50.00wt.%, 55.00wt.%, 60.00wt.%.

[0080] In a preferred embodiment, the medicament of the present invention is a tablet comprising the pharmaceutical composition according to the proposed invention (wt. %):

[0081] 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione crystalline form 20.0-30.0%

[0082] excipient:

[0083]

[0084] and film coating.

[0085] In a more preferred embodiment, the medicament of the present invention is a tablet comprising the pharmaceutical composition according to the proposed invention (wt. %):

[0086] Crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione 22.2%

[0087] excipient:

[0088]

[0089] and dispersion film coating.

[0090] In a still more preferred embodiment, the pharmaceutical composition according to the present invention comprises:

[0091] 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione crystalline form 40.00 mg

[0092] excipient:

[0093]

[0094] And dispersion film coating: Opadry II 85F18422 (white) - 7.20 mg.

[0095] The drug of the present invention can be administered orally, parenterally, by inhalation, subcutaneously, intraperitoneally, topically, or rectally (but not limited to). The therapeutic dose of the drug comprising the new crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention or the active drug substance or pharmaceutical composition, or the pharmaceutical composition for treating cough comprising a therapeutically effective amount of the new crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention, can be adjusted in the patient according to the therapeutic effectiveness and bioavailability of the active ingredients in the body, their metabolism and excretion rate from the body, and according to the patient's age, gender and disease stage.

[0096] Crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, pharmaceutical composition comprising the same, and use of the drug

[0097] The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, the active drug substance, the pharmaceutical composition and the medicament comprising the same can be used for treating cough.

[0098] The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention, the active pharmaceutical substance and the pharmaceutical composition comprising the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione can be used for preparing the medicine of the present invention.

[0099] The cough to be treated and / or prevented according to the present invention may include dry cough, refractory cough, chronic cough of unknown etiology, cough caused by respiratory diseases caused by bronchial asthma, COPD, idiopathic pulmonary fibrosis, lung cancer. Preferably, the cough to be treated and / or prevented according to the present invention is a dry cough.

[0100] In another embodiment, the cough to be treated and / or prevented according to the present invention may be a cough caused by a viral infection. Preferably, the cough may be caused by an acute respiratory viral infection (ARVI). Such an acute respiratory viral infection refers to an infectious disease affecting the mucous membranes of the upper respiratory tract.

[0101] In one embodiment of the present invention, the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione in the pharmaceutical composition or drug of the present invention is administered in an amount of 5 mg to 200 mg per day, for example, 1-3 times a day, 5 to 20 mg each time. The most preferred dosage selection can be determined based on the age and / or weight of the patient and the nature of the symptoms exhibited.

[0102] In a preferred embodiment of the present invention, the treatment of cough comprises symptomatic treatment, ie treatment aimed at eliminating the symptoms of cough, regardless of other possible etiological mechanisms of the disease.

[0103] BRIEF DESCRIPTION OF THE DRAWINGS

[0104] Figure 1 - A powder X-ray diffraction pattern showing the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention.

[0105] Figure 2 - Powder X-ray diffraction pattern showing the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention and its comparison with the calculated pattern. The blue curve is experimental, the red curve is calculated, and the grey curve is the difference between them.

[0106] Figure 3 - A general view showing a molecule of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione in a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione of the present invention. The structure was identified by X-ray diffraction (XRD) analysis.

[0107] Unless otherwise specified, all technical and specific terms used in this context have their common meanings in the art.

[0108] Implementation of the invention

[0109] The present invention is further explained, but not limited thereto, by the following examples, which illustrate the present invention.

[0110] Example 1. Preparation of a new crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0111] A crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was prepared according to the following procedure.

[0112] A 3.0 g sample of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione was ground in a porcelain mortar for 1-2 minutes. Afterwards, the resulting powder was dissolved in 20 ml of heptane heated to 75°C with stirring. Next, the mixture was placed in a refrigerator and kept at a temperature of +5°C for 24 hours. The precipitated crystals were filtered and dried under reduced pressure (100 mm Hg) until the weight of the crystals stopped decreasing with further drying. 2.7 g (90%) of 1-(2-(1H-imidazole-4-yl)ethyl)piperidine-2,6-dione was prepared in the form of a white crystalline powder.

[0113] The powder X-ray diffraction patterns of the obtained crystalline forms were recorded on a Bruker D8 Advance diffractometer using reflection geometry equipped with a slit system for monochromatization and focusing. and the position-sensitive LynxEye detector, in 0.02° steps along 2θ angles over an angular range of 4–60°.

[0114] Figure 1 The X-ray powder diffraction pattern of the obtained crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione is shown in Table 1. The position of the 2θ angle and its relative intensity are listed.

[0115] Table 1. Angles (2θ (degrees)) ± 0.2 and relative intensities (I, %) of the crystalline forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0116]

[0117]

[0118] The powder X-ray diffraction pattern of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione includes strong peaks (maxima) at the following diffraction angles 2θ (±0.2°): 11.9, 12.6, 15.2, 16.3, 18.8, 21.5, 23.1, 23.4, 23.7, 23.8, 24.5, 26.6, 27.0, 28.3, 29.6, 29.8, 31.3, 32.3, 35.9, 36.0, 47.1, 47.2. The characteristic peaks are 16.3, 23.4, 23.7, 23.8, 24.5, 26.6, 27.0. The strongest peaks are 16.3, 23.8 and 24.5.

[0119] The crystal structure of the resulting phase was identified using single crystal X-ray diffraction and full pattern refinement of the powder diffraction data array ("Rietveld method"). The measurements were performed at room temperature (296.15 K). A full view of the diffraction pattern of a sample of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and its comparison with the calculated pattern is shown in Figure 2 The blue curve represents the experiment, the red curve represents the calculation, and the grey curve represents the difference between them. The unit cell parameters are detailed in Table 2.

[0120] Table 2. Crystal structure parameters of the form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0121]

[0122] The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was also studied by X-ray diffraction (XRD). The molecule crystallizes in the orthorhombic system, space group Pbca. All measurements were performed at a temperature of 100 K using Mo Kα radiation. The overall view of the molecule is as follows Figure 3 Tables 3 and 4 list the bond lengths and angles. 10 H 13 Crystallographic information of N3O2 (M = 207.23 g / mol): orthorhombic system, space group Pbca (number 61), Z=8, T=100K, μ(MoKα)=0.096mm -1 , Dcalc=1.336g / cm 3 , 28937 reflections (5.516°≤2θ≤61.102°) were collected, of which 3149 reflections (R int =0.0410,R σ =0.0229) for further calculations.

[0123] Table 3. Calculated interatomic distances (bond lengths)

[0124]

[0125] Table 4. Calculated angles

[0126] atom atom atom Angle / ° atom atom atom Angle / ° C1 N1 C5 124.33(7) O2 C5 N1 119.50(8) C1 N1 C6 118.68(7) O2 C5 C4 122.50(8) C5 N1 C6 117.00(7) N1 C5 C4 117.99(7) C9 N2 C8 105.47(7) N1 C6 C7 110.59(7) C9 N3 C10 106.99(7) C8 C7 C6 113.27(7) O1 C1 N1 120.31(8) N2 C8 C7 121.48(8) O1 C1 C2 122.56(8) C10 C8 N2 109.16(7) N1 C1 C2 117.13(7) C10 C8 C7 129.33(8) C1 C2 C3 111.94(7) N2 C9 N3 112.01(8) C4 C3 C2 108.60(7) C8 C10 N3 106.36(7) C5 C4 C3 113.46(7)

[0127] The unit cell axis values ​​obtained in single crystal studies differ by 1-3% from the values ​​calculated based on powder X-ray diffraction data. This is due to the fact that single crystals were studied at a temperature of 100 K, whereas the powder phase was studied at room temperature.

[0128] The obtained crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione is used to prepare the active pharmaceutical ingredient (API) to constant weight by an additional drying step (drying in a CO2 stream, spray drying method, drying under vacuum, etc.). The output is a fine white powder. The finished drug substance is placed in a sealed bottle.

[0129] Example 2. Study on the storage stability of a new crystal form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0130] The stability of the active drug substance, which is a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, was evaluated by accelerated aging according to GPM.1.1.0009.15 Drug Shelf Life, RF National Pharmacopoeia. Typically, at elevated temperatures, the physicochemical processes occurring in a drug are accelerated, leading to undesirable changes in quality over time. Therefore, at elevated temperatures, the time (experimental shelf life) for keeping the controlled drug quality indicators within acceptable limits is artificially shortened.

[0131] The expected storage conditions for the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione are 3 years at a temperature not exceeding 25°C.

[0132] Storage temperature (t s ) and the shelf life (S) at elevated experimental storage temperature (t e ) under the experimental shelf life (S E ) is expressed by the van't Hoff equation:

[0133] S=K·S E ; K = A (te-ts) / 10 ;

[0134] Where A is the temperature coefficient, which is taken to be equal to 2.5.

[0135] The storage conditions chosen for the accelerated aging experiments were 28 days at 65 ° C. For the study, a sample of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was placed in a climate chamber at a temperature of 65 ° C for 28 days. Next, the X-ray diffraction pattern of the obtained sample was recorded. The absence of additional reflections in the obtained picture indicates the purity of the form and the preservation of the crystal structure. Therefore, the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione remains stable under the selected storage conditions.

[0136] Example 3. Solubility study of the new crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0137] The solubility of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was determined according to GPM.1.2.1.0005.15 Solubility, RF National Pharmacopoeia. A phosphate buffer at pH 6.8 was used as a model of human saliva.

[0138] 1.0 ml of phosphate buffer was added to 1.0 g of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and the resulting suspension was shaken continuously for 10 minutes at 25° C. The material did not completely dissolve; the solution was turbid.

[0139] Next, 1.0 ml of phosphate buffer was added to 100 mg of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione and the above procedure was repeated. The crystalline form dissolved completely. According to GPM.1.2.1.0005.15, the substance should be classified as freely soluble.

[0140] Example 4. Study on the Hygroscopicity of Crystalline Forms of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0141] The hygroscopicity of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was evaluated according to GPM.1.2.1.0010.15 Weight Loss on Drying, RF National Pharmacopoeia.

[0142] The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was placed in a climate chamber at 80% relative humidity and 25°C for 24 hours. Next, a weighed sample of the resulting material was placed in a weighing bottle and weighed to constant weight. Drying was performed in a desiccator over phosphorus (V) oxide for 12 hours. Thereafter, the weighing bottle was removed from the desiccator, covered with a lid and weighed.

[0143] Calculate the weight loss after drying using the following formula:

[0144] X=(m2-m3) / (m2-m1)

[0145] Where m1 is the weight of the weighing bottle with the lid, m2 is the weight of the substance together with the weighing bottle before drying; and m3 is the weight of the substance together with the weighing bottle after drying.

[0146] The study found that the weight loss upon drying was 1.24%, which allows the substance to be classified as slightly hygroscopic.

[0147] In an analogous manner, substances prepared according to the prior art (RU 2562773C2) were investigated.

[0148] The two dried materials were analyzed by HPLC. The material prepared according to the prior art showed a content of impurities of 5-[2-(1H-imidazol-4-yl)ethylamino]-5-oxopentanoic acid (vitaglutam) of less than 0.5 wt.%. The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione had a content of foreign impurities of less than 0.1 wt.%.

[0149] Example 5. Preparation of a pharmaceutical composition comprising a new crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0150] According to the composition disclosed in Table 2, the drug substance of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione prepared in Example 1 was used to prepare a pharmaceutical composition.

[0151] For each composition, the drug substance was mixed with the excipients listed in Table 5 and the final mixture was stirred thoroughly.

[0152] Table 5. Compositions of the pharmaceutical composition of the present invention comprising a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione as an active substance

[0153]

[0154]

[0155] Example 6. Preparation of a medicament comprising a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione

[0156] The pharmaceutical composition prepared in Example 5 was compressed on a tablet press consisting of a steel substrate with a hole having a diameter of 10 mm and two chrome-plated rods (upper punch and lower punch) placed up and down. The lower punch fixed the space in the substrate into which the pharmaceutical composition was poured. Next, the upper punch compressed the composition. The upper punch and the lower punch were then removed from the mold in sequence, and the tablet was ejected. For tableting, the first composition of the composition described in Example 5 was selected.

[0157] The drug comprising the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione was prepared in the form of a tablet having a diameter of 10 mm and a height of 3 mm. The tablet was additionally coated with Opadry II.

[0158] Tablet composition:

[0159] 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione crystalline form 40.00 mg

[0160] excipient:

[0161]

Claims

1. A crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, characterized in that: Peak positions in the powder X-ray diffraction pattern, 2θ (degrees): 16.3±0.2, 23.8±0.2 and 24.5±0.

2.

2. The crystal form according to claim 1, characterized in that Peak positions in the powder X-ray diffraction pattern obtained using Cu (Kα) radiation, 2θ (degrees): 16.3±0.2, 23.4±0.2, 23.7±0.2, 23.8±0.2, 24.5±0.2, 26.6±0.2 and 27.0±0.

2.

3. A crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione, characterized in that: The orthorhombic system of the lattice and the values ​​of the unit cell axes, (Angstroms): 9.5±0.3, 15.0±0.3 and 15.0±0.

3.

4. The crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to claim 3, characterized in that: The values ​​of the unit cell axes at room temperature (296.15K), (Angstroms): 9.4835, 15.0520 and 14.9745.

5. A pharmaceutical composition for treating and / or preventing cough, comprising a therapeutically effective amount of a crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to any one of claims 1 to 4 and at least one pharmaceutically acceptable excipient.

6. The pharmaceutical composition according to claim 5, comprising (wt.%):

7. The pharmaceutical composition according to claim 6, comprising (wt.%):

8. The pharmaceutical composition according to claim 5, comprising:

9. A medicament for treating and / or preventing cough, comprising a therapeutically effective amount of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to any one of claims 1 to 4 or a pharmaceutical composition according to any one of claims 5 to 8.

10. The drug according to claim 9, prepared in the form of tablets or capsules.

11. The drug according to claim 9, comprising:

12. Use of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to any one of claims 1 to 4 for preparing the medicament according to any one of claims 9 to 11.

13. Use of the crystalline form of 1-(2-(1H-imidazol-4-yl)ethyl)piperidine-2,6-dione according to any one of claims 1 to 4 for treating and / or preventing cough.